Transcept's Roller Coaster Year Ends with Intermezzo Approval
By Jennifer Boggs
Monday, November 28, 2011
Back in July, it looked like Transcept Pharmaceutical Inc.'s insomnia drug Intermezzo (zolpidem tartrate) was down for the count. The company, aiming to provide the first treatment specifically for middle-of-the-night waking, had just gotten a surprise second complete response letter (CRL), despite conducting the FDA-requested next-day highway driving study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.